 |
 |

Management of Chronic Obstructive Pulmonary DiseaseReply
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In Reply: In reponse to Dr Ewart, Butler et al1 reported an efficacy of 57% in preventing pneumococcal sepsis or meningitis by serotypes included in the pneumococcal vaccine, and of 65% in patients with COPD. Robinson et al2 reported that 28.6% of patients with invasive pneumococcal disease were at least 65 years of age, which suggests that the beneficial effects may be even more pronounced in the elderly population. Importantly, 86% of cases in this age group were due to serotypes included in the 23-valent polysaccharide pneumococcal vaccine. Consistent with these data, in a recent Cochrane review that Ewart cites, the authors concluded that " . . . the [pneumococcal] vaccines are effective in reducing the incidence of the more specific outcome, invasive pneumococcal disease, among adults and the immunocompetent elderly (55 years and above)."3 As pneumococcal vaccines are generally safe, we recommend vaccinating patients aged 65 years or older . . . [Full Text of this Article]
Don D. Sin, MD, MPH
don.sin@ualberta.ca
S. F. Paul Man, MD
Division of Pulmonary Medicine
Finlay A. McAlister, MD, MSc
Department of General Medicine University of Alberta Edmonton
Nick R. Anthonisen, MD, PhD
Department of Medicine University of Manitoba Winnipeg
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Management of Chronic Obstructive Pulmonary Disease
Robert M. Ewart
JAMA. 2004;291(9):1066.
EXTRACT
| FULL TEXT
Management of Chronic Obstructive Pulmonary Disease
R. Graham Barr
JAMA. 2004;291(9):1066-1067.
EXTRACT
| FULL TEXT
Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review
Don D. Sin, Finlay A. McAlister, S. F. Paul Man, and Nick R. Anthonisen
JAMA. 2003;290(17):2301-2312.
ABSTRACT
| FULL TEXT
|